Editor’s Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach

Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for idiosyncratic drug-induced liver injury (DILI) in this patient population. To identify risk factors and mechanisms underlying t...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Toxicol Sci
Main Authors: Mosedale, Merrie, Kim, Yunjung, Brock, William J., Roth, Sharin E., Wiltshire, Tim, Eaddy, J. Scott, Keele, Gregory R., Corty, Robert W., Xie, Yuying, Valdar, William, Watkins, Paul B.
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2017
נושאים:
Collaborative Cross and Tolvaptan-Induced Liver Injury
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075566/
https://ncbi.nlm.nih.gov/pubmed/28115652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/toxsci/kfw269
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים